HC Wainwright & Co. Reiterates Buy on Aadi Bioscience, Maintains $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Aadi Bioscience (NASDAQ:AADI), maintaining a $45 price target.

August 10, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aadi Bioscience's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating with a $45 price target.
Analyst ratings often influence the short-term price movement of stocks. A 'Buy' rating suggests that the analyst believes the stock will outperform the market, which can lead to increased investor interest and potentially a rise in stock price. The maintained price target of $45 also indicates the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100